Immunodermatology News

A number of approaches and therapies may be necessary to treat cutaneous dermatomyositis, according to a presenter at the 2021 Congress of Clinical Rheumatology-West.

Hidradenitis suppurativa patients with skin of color are more likely to have surgical intervention than white patients, according to a poster presented at the Skin of Color Update virtual meeting.

Steroid alternatives should be considered for patients with bullous pemphigoid, who are most likely to be treated with oral prednisolone, according to a study.

The NIH has launched a clinical trial to examine antibody responses to a COVID-19 vaccine booster dose in patients with autoimmune disease who failed to respond to the initial vaccine regimen.

The mean annual direct and indirect costs related to idiopathic inflammatory myopathies are three to five times higher than in the general population, and begin increasing 2 years before diagnosis, according to data from a Swedish registry.

Bimekizumab showed clinically meaningful improvements in hidradenitis suppurativa in a phase 2 trial.

So-called “COVID toes” and other cutaneous manifestations of the virus are not the only dermatologic challenges that a rheumatologist may face, according to a presenter at the 2021 Congress of Clinical Rheumatology-East.

Greater training in hidradenitis suppurativa diagnosis and treatment in pediatric patients could lead to more effective management and fewer high-cost emergency department visits, according to a retrospective cohort study.

A thorough physical exam and attention to a patient’s medical history are integral to differentiating dermatomyositis from cutaneous dermatomyositis with similar features, according to a presenter here.

Providers should avoid monotherapy when treating hidradenitis suppurativa, and instead use a “layered and rotated” approach that also addresses the isolating psychosocial aspects of the disease, noted a speaker here.